 Unlike other drugs that were available that just address symptoms of CF, the drug candidate was intended to address the underlying cause of CF.The company in which CFF invested was Aurora Biosciences; CFF provided $30 million for Aurora to identify and develop up to three drug candidates.The unusual nature of the arrangement was widely noted.